Lorlatinib

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Lorlatinib and local guidelines before prescribing.

Tyrosine kinase inhibitor

Mechanism

ALK tyrosine kinase inhibitor.

Uses

ALK-positive non-small-cell lung cancer.

Dosing

No dose is given in the chapters. See the BNF.

Side effects

Hypercholesterolaemia, cognitive and mood effects, oedema, weight gain.

Interactions

Strong CYP3A4 inducers contraindicated.

Contraindications and cautions

Strong CYP3A inducers

Monitoring

Lipids, ECG

Pregnancy and breastfeeding

Contraindicated

Renal and hepatic impairment

Caution in severe hepatic impairment

Overdose and reversal

Supportive

Special advice

Lipids and PR interval monitoring.

More from the textbook: uses, cautions and other points
Where it is discussed in the book